A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
OncoResponse, Inc.
Massachusetts General Hospital
Kineta Inc.
University Health Network, Toronto
Jules Bordet Institute
Revolution Medicines, Inc.
Imperial College London
Shanghai Fengxian District Central Hospital
Beijing Immunochina Medical Science & Technology Co., Ltd.
CureVac
SpeciCare
Fundacion Clinic per a la Recerca Biomédica
Mie University
Threshold Pharmaceuticals
Institut National de la Santé Et de la Recherche Médicale, France